Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
- PMID: 27363491
- DOI: 10.1038/modpathol.2016.109
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
Abstract
Multiple independent studies have shown that tumor-infiltrating lymphocytes (TIL) are prognostic in breast cancer with potential relevance for response to immune-checkpoint inhibitor therapy. Although many groups are currently evaluating TIL, there is no standardized system for diagnostic applications. This study reports the results of two ring studies investigating TIL conducted by the International Working Group on Immuno-oncology Biomarkers. The study aim was to determine the intraclass correlation coefficient (ICC) for evaluation of TIL by different pathologists. A total of 120 slides were evaluated by a large group of pathologists with a web-based system in ring study 1 and a more advanced software-system in ring study 2 that included an integrated feedback with standardized reference images. The predefined aim for successful ring studies 1 and 2 was an ICC above 0.7 (lower limit of 95% confidence interval (CI)). In ring study 1 the prespecified endpoint was not reached (ICC: 0.70; 95% CI: 0.62-0.78). On the basis of an analysis of sources of variation, we developed a more advanced digital image evaluation system for ring study 2, which improved the ICC to 0.89 (95% CI: 0.85-0.92). The Fleiss' kappa value for <60 vs ≥60% TIL improved from 0.45 (ring study 1) to 0.63 in RS2 and the mean concordance improved from 88 to 92%. This large international standardization project shows that reproducible evaluation of TIL is feasible in breast cancer. This opens the way for standardized reporting of tumor immunological parameters in clinical studies and diagnostic practice. The software-guided image evaluation approach used in ring study 2 may be of value as a tool for evaluation of TIL in clinical trials and diagnostic practice. The experience gained from this approach might be applicable to the standardization of other diagnostic parameters in histopathology.
Similar articles
-
Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.Ann Surg Oncol. 2016 Jul;23(7):2242-8. doi: 10.1245/s10434-016-5173-8. Epub 2016 Mar 10. Ann Surg Oncol. 2016. PMID: 26965699
-
Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis.Breast Cancer Res Treat. 2018 Sep;171(2):295-302. doi: 10.1007/s10549-018-4842-7. Epub 2018 Jun 5. Breast Cancer Res Treat. 2018. PMID: 29869774
-
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Adv Anat Pathol. 2017. PMID: 28777142 Free PMC article. Review.
-
Multi-assistant methods improve stromal tumor-infiltrating lymphocytes (sTILs) assessment in breast cancer: results of multi-institutional ring studies.ESMO Open. 2025 May;10(5):105095. doi: 10.1016/j.esmoop.2025.105095. Epub 2025 May 14. ESMO Open. 2025. PMID: 40373351 Free PMC article.
-
The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.Ann Oncol. 2021 Oct;32(10):1236-1244. doi: 10.1016/j.annonc.2021.07.007. Epub 2021 Jul 24. Ann Oncol. 2021. PMID: 34311075 Review.
Cited by
-
An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer.Clin Cancer Res. 2021 Oct 15;27(20):5557-5565. doi: 10.1158/1078-0432.CCR-21-0325. Epub 2021 Jun 4. Clin Cancer Res. 2021. PMID: 34088723 Free PMC article.
-
Application and challenge of HER2DX genomic assay in HER2+ breast cancer treatment.Am J Cancer Res. 2024 Sep 15;14(9):4218-4235. doi: 10.62347/JWHA6355. eCollection 2024. Am J Cancer Res. 2024. PMID: 39417184 Free PMC article. Review.
-
ONEST (Observers Needed to Evaluate Subjective Tests) Analysis of Stromal Tumour-Infiltrating Lymphocytes (sTILs) in Breast Cancer and Its Limitations.Cancers (Basel). 2023 Feb 14;15(4):1199. doi: 10.3390/cancers15041199. Cancers (Basel). 2023. PMID: 36831541 Free PMC article.
-
Tumor budding and fibrotic focus-proposed grading system for tumor budding in invasive carcinoma no special type of the breast.Virchows Arch. 2022 Aug;481(2):161-190. doi: 10.1007/s00428-022-03337-0. Epub 2022 Jun 13. Virchows Arch. 2022. PMID: 35695928 Free PMC article.
-
External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices.Cancers (Basel). 2022 Aug 2;14(15):3762. doi: 10.3390/cancers14153762. Cancers (Basel). 2022. PMID: 35954426 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical